http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022514867-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022514867-A |
| titleOfInvention | Use of anti-CCR7 MAB for the prevention or treatment of graft-versus-host disease (GvHD) |
| abstract | The present invention is CCR7 acceptance for use as a novel therapeutic agent in the prevention and / or treatment of graft-versus-host disease (GVHD), preferably in hematopoietic stem cell transplantation (HSCT), more preferably in allogeneic hematopoietic stem cell transplantation. Provided are novel uses and methods comprising an antibody that binds to the body or an antigen-binding fragment thereof. The GVHD of the present invention can be acute (aGVHD) and / or chronic (cGVHD), preferably acute. Antigens and antigen-binding fragments can selectively eliminate CCR7-expressing immune cells ex vivo or in vitro, selectively killing CCR7 receptor-expressing immune cells and developing GVHD. And it is possible in vivo to impair / block the migration and activation of said immune cells involved in progression. The use of the antibody to eliminate, kill, and impair / block the migration and activation of CCR7 receptor-expressing immune cells is disclosed and thus GVHD in both acute and chronic forms. Provide alternative therapies for prevention and treatment. [Selection diagram] None |
| priorityDate | 2018-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 249.